Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2012

View Archived Issues

Apogenix reports phase II APG-101 results

New orexin receptor antagonists patented by Actelion Pharmaceuticals

Phase II program on transdermal patch for schizophrenia begins

Study links ABC transporter gene polymorphisms to liver transplant outcomes

Pharmacodynamic efficacy of E-2096 described in animals and humans

Chinese researchers discover novel DPP IV inhibitors

Abbott presents new GSK-3 beta inhibitors

Sanofi reports novel Akt phosphorylation inhibitors

Spanish group synthesizes novel anti-inflammatory agents

Dainippon Sumitomo reviews events of first quarter fiscal 2012

StemCells receives California Institute for Regenerative Medicine award

GlaxoSmithKline develops novel orexin receptor antagonists

FDA advisory committee recommends ocriplasmin approval

Abbott and Enanta design new HCV NS3 protease inhibitors

Genentech reports on BREVACTA trial

SNPs affecting gene expression linked to late-onset Alzheimer's disease risk

NIH funds development of tissue chips to predict drug safety

Chugai Pharmaceutical profiles progress of second quarter 2012

Nuvo Research receives additional funding commitment for reformulated WF-10

Advinus Therapeutics and P2D Bioscience collaborate on ADHD

International collaboration yields new solution to defect regeneration in load-bearing long bones

Arena Pharmaceuticals transfers NDA rights to Eisai

Roche and Areva Med collaborate on radioimmunotherapy

Takeda resubmits alogliptin product NDAs

Basilea Pharmaceutica seeks European approval of antibiotic to treat pneumonia in hospitals

Shionogi seeks Japanese approval of combination drug for hypertension

Tokyo Institute of Technology and Astellas Pharma collaborate on neglected tropical diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...